Cellid Co. Ltd (299660) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.031x

Based on the latest financial reports, Cellid Co. Ltd (299660) has a cash flow conversion efficiency ratio of -0.031x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.30 Billion ≈ $-1.56 Million USD) by net assets (₩74.21 Billion ≈ $50.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Cellid Co. Ltd to measure how many days the company can operate on defensive assets alone.

Cellid Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Cellid Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Cellid Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cellid Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
APS Holdings Corporation KQ:054620	-0.008x
Y/KNOT S.A. AT:YKNOT	N/A
Selangor Dredging Bhd KLSE:2224	0.216x
Lument Finance Trust Inc NYSE:LFT	0.006x
Techbond Group Bhd KLSE:5289	0.052x
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret IS:ANGEN	-0.002x
Unick Corporation KQ:011320	0.105x
eHealth Inc NASDAQ:EHTH	0.037x

Annual Cash Flow Conversion Efficiency for Cellid Co. Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Cellid Co. Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Cellid Co. Ltd market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩74.21 Billion ≈ $50.29 Million	₩-10.22 Billion ≈ $-6.92 Million	-0.138x	+31.65%
2024-12-31	₩51.20 Billion ≈ $34.70 Million	₩-10.32 Billion ≈ $-6.99 Million	-0.201x	-14.66%
2023-12-31	₩40.50 Billion ≈ $27.44 Million	₩-7.12 Billion ≈ $-4.82 Million	-0.176x	+67.73%
2022-12-31	₩22.44 Billion ≈ $15.21 Million	₩-12.22 Billion ≈ $-8.28 Million	-0.544x	-157.14%
2021-12-31	₩38.76 Billion ≈ $26.27 Million	₩-8.21 Billion ≈ $-5.56 Million	-0.212x	-166.09%
2020-12-31	₩47.30 Billion ≈ $32.05 Million	₩-3.76 Billion ≈ $-2.55 Million	-0.080x	-112.62%
2019-12-31	₩51.33 Billion ≈ $34.79 Million	₩-1.92 Billion ≈ $-1.30 Million	-0.037x	+74.67%
2018-12-31	₩13.50 Billion ≈ $9.15 Million	₩-1.99 Billion ≈ $-1.35 Million	-0.148x	-159.53%
2017-12-31	₩-5.53 Billion ≈ $-3.75 Million	₩-1.37 Billion ≈ $-929.53K	0.248x	-96.60%
2016-12-31	₩-205.83 Million ≈ $-139.49K	₩-1.50 Billion ≈ $-1.02 Million	7.306x	--

About Cellid Co. Ltd

KQ:299660 Korea Biotechnology

Market Cap

$52.38 Million

₩77.30 Billion KRW

Market Cap Rank

#21790 Global

#1303 in Korea

Share Price

₩2620.00

Change (1 day)

-3.14%

52-Week Range

₩2315.00 - ₩5690.00

All Time High

₩127128.20